Literature DB >> 27815778

High target attainment for β-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied.

H Woksepp1,2, A Hällgren3, S Borgström4, F Kullberg5, A Wimmerstedt6, A Oscarsson7,8, P Nordlund9, M-L Lindholm4, J Bonnedahl10, L Brudin11, B Carlsson12, T Schön13,14.   

Abstract

Patients in the intensive care unit (ICU) are at risk for suboptimal levels of β-lactam antibiotics, possibly leading to poor efficacy. Our aim was to investigate whether the actual minimum inhibitory concentration (MIC) compared to the more commonly used arbitrary epidemiological cut-off values (ECOFFs) would affect target attainment in ICU patients on empirical treatment with broad-spectrum β-lactam antibiotics and to identify risk factors for not reaching target. In a prospective, multicenter study, ICU patients ≥18 years old and treated with piperacillin/tazobactam, meropenem, or cefotaxime were included. Clinical and laboratory data were recorded. Serum trough antibiotic levels from three consecutive days were analyzed by liquid chromatography-mass spectrometry (LC-MS). The target was defined as the free trough concentration above the MIC (100% fT>MIC). MICECOFF was used as the target and, when available, the actual MIC (MICACTUAL) was applied. The median age of the patients was 70 years old, 52% (58/111) were males, and the median estimated glomerular filtration rate (eGFR) was 48.0 mL/min/1.73 m2. The rate of patients reaching 100% fT > MICACTUAL was higher (89%, 31/35) compared to the same patients using MICECOFF (60%, p = 0.002). In total, 55% (61/111) reached 100% fT > MICECOFF. Increased renal clearance was independently associated to not reaching 100% fT > MICECOFF. On repeated sampling, >77% of patients had stable serum drug levels around the MICECOFF. Serum concentrations of β-lactam antibiotics vary extensively between ICU patients. The rate of patients not reaching target was markedly lower for the actual MIC than when the arbitrary MIC based on the ECOFF was used, which is important to consider in future studies.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27815778     DOI: 10.1007/s10096-016-2832-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  27 in total

1.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

2.  Editorial commentary: Are blood concentrations enough for establishing pharmacokinetic/pharmacodynamic relationships?

Authors:  William A Craig
Journal:  Clin Infect Dis       Date:  2014-01-26       Impact factor: 9.079

Review 3.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.

Authors:  M Dreetz; J Hamacher; J Eller; K Borner; P Koeppe; T Schaberg; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

5.  Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations.

Authors:  Andrew A Udy; Julie M Varghese; Mahdi Altukroni; Scott Briscoe; Brett C McWhinney; Jacobus P Ungerer; Jeffrey Lipman; Jason A Roberts
Journal:  Chest       Date:  2012-07       Impact factor: 9.410

Review 6.  Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?

Authors:  Angela Huttner; Stephan Harbarth; William W Hope; Jeffrey Lipman; Jason A Roberts
Journal:  J Antimicrob Chemother       Date:  2015-07-17       Impact factor: 5.790

7.  The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs.

Authors:  Alexis Tabah; Jan De Waele; Jeffrey Lipman; Jean Ralph Zahar; Menino Osbert Cotta; Greg Barton; Jean-Francois Timsit; Jason A Roberts
Journal:  J Antimicrob Chemother       Date:  2015-07-13       Impact factor: 5.790

Review 8.  Pharmacokinetic evaluation of piperacillin-tazobactam.

Authors:  Yoshiro Hayashi; Jason A Roberts; David L Paterson; Jeffrey Lipman
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-08       Impact factor: 4.481

9.  Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species.

Authors:  Peggy C Kohner; Frans J L Robberts; Franklin R Cockerill; Robin Patel
Journal:  J Clin Microbiol       Date:  2009-06-03       Impact factor: 5.948

10.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

View more
  4 in total

1.  Quantitative Analysis of Gentamicin Exposure in Neonates and Infants Calls into Question Its Current Dosing Recommendations.

Authors:  Tamara van Donge; Marc Pfister; Julia Bielicki; Chantal Csajka; Frederique Rodieux; John van den Anker; Aline Fuchs
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

2.  Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature.

Authors:  Stan J F Hartman; Roger J Brüggemann; Lynn Orriëns; Nada Dia; Michiel F Schreuder; Saskia N de Wildt
Journal:  Clin Pharmacokinet       Date:  2020-02       Impact factor: 6.447

3.  Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study.

Authors:  Paul Chabert; Judith Provoost; Sabine Cohen; Céline Dupieux-Chabert; Laurent Bitker; Tristan Ferry; Sylvain Goutelle; Jean-Christophe Richard
Journal:  Ann Intensive Care       Date:  2022-09-30       Impact factor: 10.318

4.  Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).

Authors:  Alan Abdulla; Annemieke Dijkstra; Nicole G M Hunfeld; Henrik Endeman; Soma Bahmany; Tim M J Ewoldt; Anouk E Muller; Teun van Gelder; Diederik Gommers; Birgit C P Koch
Journal:  Crit Care       Date:  2020-09-15       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.